5 min listen
BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
ratings:
Length:
4 minutes
Released:
Apr 4, 2024
Format:
Podcast episode
Description
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.
Released:
Apr 4, 2024
Format:
Podcast episode
Titles in the series (99)
June 4 Issue Introduction: Joseph E. Safdieh, MD, FAAN, Editor-in-Chief of Neurology Today provides an overview of topics covered in the June 4, 2020 issue. by Neurology Today in 5